Literature DB >> 3838694

Atracurium and severe hepatic disease: a case report.

H K Gyasi, M Naguib.   

Abstract

Atracurium is a new non-depolarising neuromuscular blocking agent, metabolized through Hofmann elimination. A case is presented in which a 45-year-old patient with severe liver disease showed a decreased response to atracurium. The possible causes of resistance to atracurium are discussed. We conclude that atracurium may be used in patients with severe hepatic disease.

Entities:  

Mesh：

Substances：

Year:  1985        PMID： 3838694     DOI： 10.1007/bf03010043

Source DB:  PubMed          Journal:  Can Anaesth Soc J        ISSN： 0008-2856


  16 in total

1.  The binding of d-tubocurarine chloride to plasma proteins.

Authors:  L ALADJEMOFF; S DIKSTEIN; E SHAFRII
Journal:  J Pharmacol Exp Ther       Date:  1958-05       Impact factor: 4.030

2.  Resistance to d-tubocurarine chloride in the presence of liver damage.

Authors:  J W DUNDEE; T C GRAY
Journal:  Lancet       Date:  1953-07-04       Impact factor: 79.321

3.  Serum cholinesterase activity in the normal individual and in people with liver disease.

Authors:  K KAUFMAN
Journal:  Ann Intern Med       Date:  1954-09       Impact factor: 25.391

4.  Sensitivity to tubocurarine and alcuronium with special reference to plasma protein pattern.

Authors:  J Stovner; L Theodorsen; E Bjelke
Journal:  Br J Anaesth       Date:  1971-04       Impact factor: 9.166

5.  Correlation between tubocurarine requirements and plasma protein pattern.

Authors:  A Baraka; F Gabali
Journal:  Br J Anaesth       Date:  1968-02       Impact factor: 9.166

6.  In vitro degradation of atracurium in human plasma.

Authors:  R A Merrett; C W Thompson; F W Webb
Journal:  Br J Anaesth       Date:  1983-01       Impact factor: 9.166

7.  Modification of atracurium blockade by halothane and by suxamethonium. A review of clinical experience.

Authors:  J A Stirt; R L Katz; A L Murray; D L Schehl; C Lee
Journal:  Br J Anaesth       Date:  1983       Impact factor: 9.166

8.  Pharmacological action of breakdown products of atracurium and related substances.

Authors:  D J Chapple; J S Clark
Journal:  Br J Anaesth       Date:  1983       Impact factor: 9.166

9.  Atracurium: conception and inception.

Authors:  J B Stenlake; R D Waigh; J Urwin; G H Dewar; G G Coker
Journal:  Br J Anaesth       Date:  1983       Impact factor: 9.166

10.  PLASMA ESTERASE ACTIVITY IN PATIENTS WITH LIVER DISEASE AND THE NEPHROTIC SYNDROME.

Authors:  H G Kunkel; S M Ward
Journal:  J Exp Med       Date:  1947-09-30       Impact factor: 14.307
View more
  3 in total

Review 1.  Influence of renal and hepatic function on pharmacodynamics and pharmacokinetics of non-depolarizing muscle relaxants.

Authors:  L H Booij
Journal:  Pharm Weekbl Sci       Date:  1987-04-24

2.  Antiestrogenic drugs and atracurium--a possible interaction?

Authors:  M Naguib; H K Gyasi
Journal:  Can Anaesth Soc J       Date:  1986-09

3.  Atracurium for short surgical procedures: a comparison with succinylcholine.

Authors:  H K Gyasi; M Naguib; Y Adu-Gyamfi
Journal:  Can Anaesth Soc J       Date:  1985-11
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.